≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat
    ≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat

    Research use only · Not for human or veterinary use

    PEG MGF research peptide - high purity lyophilized powder for laboratory research

    2MG

    $66
    3ml Vial
    In Stock
    Bulk Discounts

    Buy 3+ for $62.70 each and save 5%

    Buy 5+ for $59.40 each and save 10%

    Buy 10+ for $56.10 each and save 15%

    This product is for research purposes only. Not for human consumption.

    Purity: >98% (HPLC verified)

    Formulation: Lyophilized powder (Pegylated)

    Molecular Formula: C37H51N9O10S (+ PEG)

    Molecular Weight: ~1000-2000 g/mol

    CAS Number: N/A

    PubChem CID: N/A

    PEG MGF

    Growth Factors

    Overview

    PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of mechano growth factor (MGF), a splice variant of the IGF-1 gene. In vivo, MGF is expressed in tissues like muscle in response to mechanical stimuli.

    PEGylation

    PEG-MGF is created by covalently attaching polyethylene glycol (PEG) polymers to the MGF peptide, a process known as PEGylation. Native MGF has a short half-life in plasma. The PEGylation process is intended to increase the hydrodynamic size of the molecule, which may extend its circulation time by slowing renal filtration and shielding it from proteolytic enzymes.

    PEGylation is a chemical strategy that has been used in the development of some approved pharmaceutical products. However, the use of this strategy for other materials does not imply any characterized profile or regulatory approval for this research compound.

    Pharmacokinetic Profile

    The PEGylation of MGF is designed to extend its half-life from minutes to hours or longer, depending on the specific PEG chain modifications. This alteration is intended to change the peptide's activity from a locally-acting factor to one with potential for systemic distribution.

    Research Status

    This peptide is understood to act via the IGF-1 receptor, activating downstream signaling pathways involved in protein synthesis and cell proliferation. PEG-MGF is considered a research chemical. There is a lack of published, peer-reviewed studies specifically examining the pharmacokinetics, pharmacodynamics, or safety of PEG-MGF in controlled experimental models.

    Mechanism of Action

    PEG-MGF is a chemically modified version of MGF, a peptide that acts through the IGF-1 receptor (IGF1R). The PEGylation is intended to alter its pharmacokinetic properties.

    Native MGF Biology

    Native MGF is a splice variant of the IGF-1 gene (IGF-1Ec isoform) that has a different C-terminal E domain sequence compared to systemic, liver-derived IGF-1. This sequence is thought to be involved in the activation of muscle satellite cells in response to local stressors.

    Receptor Signaling

    MGF binds to the IGF-1 receptor, a receptor tyrosine kinase. This binding event initiates autophosphorylation and the recruitment of adaptor proteins, leading to the activation of the PI3K/Akt/mTOR and MAPK signaling cascades. These pathways are involved in cellular processes such as protein synthesis, cell survival, and proliferation.

    In studies of muscle satellite cells, MGF has been observed to stimulate their entry into the cell cycle, promote their proliferation, and facilitate their differentiation and fusion, processes related to myogenesis.

    Pharmacological Profile

    Due to its short half-life, native MGF is thought to act primarily in an autocrine/paracrine manner within the tissue where it is produced. PEGylation alters this profile by protecting the peptide from rapid degradation, theoretically allowing for systemic distribution. The PEG modification may also affect binding to IGF binding proteins (IGFBPs).

    However, PEGylation could also potentially alter receptor binding affinity or signaling potency in ways that have not been characterized for this molecule.

    Research Findings

    Published nonclinical literature relevant to this material's molecular targets and experimental models is listed below for independent review. Findings involving other preparations or experimental systems should not be attributed to this research material.

    Research Applications

    • Systemic delivery of IGF/MGF analogs
    • PEGylation and peptide modification
    • In vitro models of myogenesis
    • Studies on satellite cell activation
    • Comparative pharmacology of IGF analogs
    • Pharmacokinetic profiling of pegylated peptides
    • Studies on sustained-release peptide formulations

    Laboratory Handling & Limitations

    This material is supplied solely for in vitro and other nonclinical laboratory research. It is not for human or veterinary use, consumption, administration, therapeutic use, or diagnostic use.

    Laboratory Handling

    Handle only in an appropriately equipped laboratory using applicable institutional procedures, personal protective equipment, and the storage conditions shown for the material. The purchaser is responsible for study design, handling controls, disposal, and regulatory compliance.

    Research Limitations

    Published observations involving other preparations, experimental systems, or study populations do not establish the identity, performance, or suitability of this research material for any particular experiment.

    Scientific References

    1. Philippou, A., et al. (2009). Masticatory muscles of mouse do not undergo atrophy in space. The FASEB Journal, 23(1), 218-226.

    Research Use Only

    This product is intended for research purposes only and is not for human consumption, therapeutic use, or diagnostic applications. Please ensure compliance with all applicable regulations and institutional guidelines.